Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0000576

Lorazepam for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

(±)-Lorazepam, 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H10Cl2N2O2
CAS Number:
846-49-1
Molecular Weight:
321.16
MDL number:
MFCD00063406
UNSPSC Code:
41116107
PubChem Substance ID:
329831029
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

lorazepam

manufacturer/tradename

EDQM

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

OC1N=C(c2ccccc2Cl)c3cc(Cl)ccc3NC1=O

InChI

1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)

InChI key

DIWRORZWFLOCLC-UHFFFAOYSA-N

Gene Information

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Lorazepam for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1370327

Lorazepam Related Compound A, United States Pharmacopeia (USP) Reference Standard

L0750500

Lorazepam, European Pharmacopoeia (EP) Reference Standard

1370305

Lorazepam, United States Pharmacopeia (USP) Reference Standard

1370338

Lorazepam Related Compound B, United States Pharmacopeia (USP) Reference Standard

Y0000718

Lorazepam impurity D, European Pharmacopoeia (EP) Reference Standard

1370349

Lorazepam Related Compound C, United States Pharmacopeia (USP) Reference Standard

1370350

Lorazepam Related Compound D, United States Pharmacopeia (USP) Reference Standard

1370360

Lorazepam Related Compound E, United States Pharmacopeia (USP) Reference Standard

BP434

Lorazepam, British Pharmacopoeia (BP) Reference Standard

BP376

6-Chloro-4-(2-chlorophenyl)quinazoline-2-carboxaldehyde, British Pharmacopoeia (BP) Reference Standard

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361d

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

G Marti et al.
Human & experimental toxicology, 32(3), 332-334 (2012-11-24)
Ritalin® (methylphenidate) is an amphetamine-like prescription stimulant commonly used in the treatment of attention deficit hyperactivity disorder in children and adults. Recently, the recreational use of Ritalin has increased, particularly among young adults. Well-known symptoms of intoxication include signs of
Natalie L Jacobowski et al.
Journal of psychiatric practice, 19(1), 15-28 (2013-01-22)
Delirious mania is a severe but under-recognized neuropsychiatric syndrome characterized by the rapid onset of delirium, mania, and psychosis, not associated with a prior toxicity, physical illness, or mental disorder. Catatonia is often a prominent feature of the syndrome. While
Jason T McMullan et al.
Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors, 17(1), 1-7 (2012-11-15)
The choice of the optimal benzodiazepine to treat prehospital status epilepticus is unclear. Lorazepam is preferred in the emergency department, but concerns about nonrefrigerated storage limits emergency medical services (EMS) use. Midazolam is increasingly popular, but its heat stability is
Olugbenga A Akingbola et al.
American journal of critical care : an official publication, American Association of Critical-Care Nurses, 21(6), 456-459 (2012-11-03)
A 6-year-old girl displayed symptoms of serotonin syndrome after accidental ingestion of Vyvanse (lisdexamfetamine dimesylate). Dexmedetomidine was administered because of persistent neuromuscular hyperactivity and severe agitation despite initial therapy with benzodiazepines. Some children show a paradoxical reaction to benzodiazepines, and
Feridun Bülbül et al.
The journal of ECT, 29(1), e1-e1 (2013-02-21)
Despite having been previously associated with schizophrenia, catatonia is more often associated with mood disorders and factors related to general medical conditions. Benzodiazepines are recommended as the first option in treatment of catatonia. For patients who do not sufficiently respond
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service